

Appl. No. 09/302,863  
Amend. & Reply dated Nov. 2, 2004  
Resp. to OA dated May 3, 2004

## 2. Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-14 (cancelled)

15. (Currently amended) A method of screening a test compound comprising the steps of:

- a. forming a composition comprising
  - (i) a first isolated protein, comprising a polypeptide selected from the group consisting of:
    - (a) the polypeptide of SEQ ID NO:2;
    - (b) a polypeptide comprising amino acids 2-166 of SEQ ID NO:2;
    - (c) a fragment of the polypeptide of SEQ ID NO:2; or
    - (d) a polypeptide encoded by a nucleic acid sequence that is at least 95% identical to SEQ ID NO:1;wherein said fragment of (i)(c) and said polypeptides of (i)(d) bind SEQ ID NO:4;
  - (ii) a second isolated protein, comprising a polypeptide selected from the group consisting of:
    - (a) the polypeptide of SEQ ID NO:4;
    - (b) a polypeptide comprising amino acids 123-285 of SEQ ID NO:4; or
    - (c) a polypeptide comprising amino acids 73-285 of SEQ ID NO:4;
    - ~~(d) a fragment of the polypeptide of SEQ ID NO:4; or~~
    - ~~(e) a polypeptide encoded by a nucleic acid sequence that is at least 90% identical to SEQ ID NO:3;~~wherein said fragment of (ii)(d) and said polypeptides of (ii)(e) bind SEQ ID NO:2; and
  - (iii) a test compound; and
- b. assaying for the level of interaction of the protein of (i) and the protein of (ii); such that if the level obtained in step (b) differs from that obtained in the absence of the test compound, a test compound that affects the interaction of the protein of (i) and the protein of (ii) is identified.

Appl. No. 09/302,863  
Amend. & Reply dated Nov. 2, 2004  
Resp. to OA dated May 3, 2004

16. *(Previously presented)* The method of claim 15 wherein at least one of the proteins of (i) and the proteins of (ii) is labeled with a detectable moiety.
17. *(Previously presented)* The method of claim 15 wherein both the proteins of (i) and (ii) are soluble.
18. *(Previously presented)* The method of claim 17 wherein both the soluble protein of (i) and the soluble protein of (ii) are labeled with a detectable moiety.
19. *(Previously presented)* The method of claim 15 wherein the test compound is an antibody.
20. *(Previously presented)* The method of claim 19 wherein the antibody is a humanized antibody.
21. *(Previously presented)* The method of claim 15 wherein the composition is formed by adding the test compound to the protein of (i) and the protein of (ii).
22. *(Previously presented)* The method of claim 15 wherein step (b) comprises determining a dissociation constant of the interaction of the protein of (i) with the protein of (ii).
23. *(Previously presented)* The method of claim 15 wherein step (b) comprises assessing activation of the protein of (i) in a cell.
24. *(Previously presented)* The method of claim 23 wherein assessing activation of the protein of (i) in a cell is measured by calcium influx.
25. *(Previously presented)* The method of claim 15 wherein the protein of (ii) is a polypeptide comprising amino acids 123-285 of SEQ ID NO:4 or a polypeptide comprising amino acids 73-285 of SEQ ID NO:4.

Appl. No. 09/302,863  
Amend. & Reply dated Nov. 2, 2004  
Resp. to OA dated May 3, 2004

26. (*Previously presented*) The method of claim 25 wherein the polypeptide comprising amino acids 123-285 of SEQ ID NO:4 or the polypeptide comprising amino acids 73-285 of SEQ ID NO:4 further comprises a leucine zipper domain.

27. (*Previously presented*) The method of claim 15 wherein the protein of (i) is a polypeptide comprising amino acids 2-166 of SEQ ID NO:2.

28. (*Previously presented*) The method of claim 27 wherein the polypeptide comprising amino acids 2-166 of SEQ ID NO:2 further comprises a Fc domain.

29. (*Previously presented*) A method of screening a test compound comprising the steps of:

- a. forming a composition comprising
  - (i) an isolated protein selected from the group consisting of:
    - (a) the polypeptide of SEQ ID NO:2;
    - (b) a polypeptide comprising amino acids 2-166 of SEQ ID NO:2;and
    - (c) a fragment of the polypeptide of SEQ ID NO:2; wherein said fragment binds SEQ ID NO:4;
  - (ii) the polypeptide of SEQ ID NO:4; and
  - (iii) a test compound; and
- b. assaying for the level of interaction of the protein of (i) and the protein of (ii); such that if the level obtained in step (b) differs from that obtained in the absence of the test compound, a test compound that affects the interaction of the protein of (i) and the protein of (ii) is identified.

30. (*Previously presented*) A method of screening a test compound comprising the steps of:

- a. forming a composition comprising
  - (i) the polypeptide of SEQ ID NO:2;
  - (ii) an isolated protein selected from the group consisting of:
    - (a) the polypeptide of SEQ ID NO:4;
    - (b) a polypeptide comprising amino acids 123-285 of SEQ ID NO:4;

Appl. No. 09/302,863  
Amend. & Reply dated Nov. 2, 2004  
Resp. to OA dated May 3, 2004

- (c) a polypeptide comprising amino acids 73-285 of SEQ ID NO:4;  
and
  - (d) a fragment of the polypeptide of SEQ ID NO:4; wherein said fragment binds SEQ ID NO:2; and
  - (iii) a test compound; and
- b. assaying for the level of interaction of the protein of (i) and the protein of (ii);  
such that if the level obtained in step (b) differs from that obtained in the absence of the test compound, a test compound that affects the interaction of the protein of (i) and the protein of (ii) is identified.

31. *(Cancelled)*

32. *(Previously presented)* A method of screening a test compound comprising the steps of:

- a. forming a composition comprising
  - (i) the polypeptide of SEQ ID NO:2;
  - (ii) the polypeptide of SEQ ID NO:4; and
  - (iii) a test compound; and
- b. assaying for the level of interaction of the polypeptide of (i) and the polypeptide of (ii);

such that if the level obtained in step (b) differs from that obtained in the absence of the test compound, a test compound that affects the interaction of the protein of (i) and the protein of (ii) is identified.

33. *(Cancelled)*

34. *(Cancelled)*

35. *(Previously presented)* The method of claim 25, wherein the polypeptide comprising amino acids 123-285 of SEQ ID NO:4 or the polypeptide comprising amino acids 73-285 of SEQ ID NO:4 further comprises a Fc domain.

36. *(Cancelled)*

Appl. No. 09/302,863  
Amend. & Reply dated Nov. 2, 2004  
Resp. to OA dated May 3, 2004

37. *(Previously presented)* The method of claim 19, wherein the antibody is human.
38. *(Previously presented)* The method of claim 19, wherein the antibody comprises a Fab fragment.
39. *(Previously presented)* The method of claim 19, wherein the antibody comprises a F(ab')<sub>2</sub> fragment.
40. *(New)* A method of screening a test compound comprising the steps of:
- a. forming a composition comprising
    - (i) a first isolated protein, comprising a polypeptide selected from the group consisting of:
      - (a) the polypeptide of SEQ ID NO:2; or
      - (b) a polypeptide comprising amino acids 2-166 of SEQ ID NO:2;
    - (ii) a second isolated protein, comprising a polypeptide selected from the group consisting of:
      - (a) the polypeptide of SEQ ID NO:4;
      - (b) a polypeptide comprising amino acids 123-285 of SEQ ID NO:4;
      - (c) a polypeptide comprising amino acids 73-285 of SEQ ID NO:4;
      - (d) a fragment of the polypeptide of SEQ ID NO:4; or
      - (e) a polypeptide encoded by a nucleic acid sequence that is at least 95% identical to SEQ ID NO:3;wherein said fragment of (ii)(d) and said polypeptides of (ii)(e) bind SEQ ID NO:2; and
  - (iii) a test compound; and
  - b. assaying for the level of interaction of the protein of (i) and the protein of (ii); such that if the level obtained in step (b) differs from that obtained in the absence of the test compound, a test compound that affects the interaction of the protein of (i) and the protein of (ii) is identified.